Trials / Unknown
UnknownNCT05472610
Study of Efficacy of BZ019 in Large B-cell Lymphoma
A Phase II Clinical Study of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Injection, for Relapsed and Refractory (R/R) Large B-cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Shanghai Mengchao Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm,open-label, non-randomized phase 2 study to determine the efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BZ019 | A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV). |
Timeline
- Start date
- 2021-06-04
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
- First posted
- 2022-07-25
- Last updated
- 2022-07-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05472610. Inclusion in this directory is not an endorsement.